State attorneys general have urged the federal government to lower the price of remdesivir. The group called on the government to allow other companies to make Gilead’s COVID-19 treatment, remdesivir, in order to make it more accessible and lower the price. (Reuters)

The Food and Drug Administration is finalizing its guidelines for CBD. The FDA has struggled to regulate CBD, a non-psychoactive compound in cannabis. The agency seems poised to release its enforcement policy on the compound. (STAT)

Apple begins depression study with UCLA. The study will use Apple products, including the iPhone and Apple Watch, to determine how sleep, physical activity, heart rate and daily routines impact symptoms of depression and anxiety. (CNBC)

A new rule requires drug companies to submit past missing clinical trial data. The rule applies to data from trials between 2007 and 2017, when companies and researchers were largely exempt from reporting data to clinicaltrials.gov. (STAT)

Bayer said it is struggling to find patients for its precision cancer drug, Vitrakvi. The company is struggling to properly identify patients with the rare tumor type to receive the treatment. “Maybe it is sometimes a little too sophisticated for physicians to diagnose patients appropriately,” said Bayer’s pharmaceutical head. (Reuters)